Artiva Biotherapeutics (ARTV) Equity Average: 2023-2025
Historic Equity Average for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $139.1 million.
- Artiva Biotherapeutics' Equity Average rose 2711.04% to $139.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.1 million, marking a year-over-year increase of 2711.04%. This contributed to the annual value of $12.3 million for FY2024, which is N/A change from last year.
- As of Q3 2025, Artiva Biotherapeutics' Equity Average stood at $139.1 million, which was down 12.45% from $158.9 million recorded in Q2 2025.
- In the past 5 years, Artiva Biotherapeutics' Equity Average ranged from a high of $193.8 million in Q4 2024 and a low of -$182.9 million during Q2 2024.
- Over the past 3 years, Artiva Biotherapeutics' median Equity Average value was $4.9 million (recorded in 2024), while the average stood at $967,389.
- Data for Artiva Biotherapeutics' Equity Average shows a peak YoY soared of 2,711.04% (in 2025) over the last 5 years.
- Over the past 3 years, Artiva Biotherapeutics' Equity Average (Quarterly) stood at -$156.7 million in 2023, then soared by 223.66% to $193.8 million in 2024, then surged by 2,711.04% to $139.1 million in 2025.
- Its Equity Average stands at $139.1 million for Q3 2025, versus $158.9 million for Q2 2025 and $177.7 million for Q1 2025.